Global BCG Vaccine for Prevent Covid-19 Market Insights, Forecast to 2028

As for March, 26 2020:

Dr. Eleanor Fish (a prominent immunologist at the University of Toronto, Canada) comments that she does not think BCG may completely eliminate infection caused by a novel coronavirus, but it is likely to mitigate the effects of a novel coronavirus on individuals.The scientists involved in the study hope that BCG vaccination may ease the burden on the health system before a specific vaccine for Covid-19 is available.

1.BCG Clinical Trials for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
A team at the university of Melbourne in Australia is using exactly the same protocol to carry out the BCG study among healthcare workers.Another team at the university of Exeter in the UK will conduct a similar study on older people.Last week, a team at the Max Planck Institute for Infection Biology in Germany announced that, inspired by Netea's work, they would carry out similar clinical trials in older people and healthcare workers with another anti-tb vaccine in development, VPM1002, a genetically modified BCG vaccine."The elderly and health care workers are bearing the brunt of the current outbreak, so they would particularly benefit if the VPM1002 vaccine could help."They said.
2.Introduction of BCG
The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. The vaccine is in most countries in the world of children after the birth of the first annual vaccination is used, the BCG vaccine to be both safe and cheap, it can prevent an average of about 60% of TB cases, children vary widely between countries.Vaccines typically produce an immune response against the target pathogen, such as antibodies that bind and neutralize one virus but do not bind to others.But BCG may also enhance the immune system's ability to fight pathogens other than tuberculosis, according to decades of published clinical and observational studies.The researchers concluded that in the first year after vaccination, about 30 percent of all known pathogens, including viruses, could be prevented.A 2014 review by the world health organization concluded that BCG appeared to reduce overall child mortality.
3.BCG can "Train" Innate Immunity
The innate immune system, composed of white blood cells such as macrophages, natural killer cells and neutrophils, should not have this memory.The team, led by professor Netea, found that BCG could survive for months in human skin, stimulating not only the t-cells and b-cells of mycobacterium memoriae, but also the white blood cells responsible for innate immunity, which can quickly respond to new infections.In a randomized placebo-controlled study published in 2018, the team showed that BCG vaccination prevented the yellow fever virus from being experimentally infected.
Market Analysis and Insights: Global BCG Vaccine for Prevent Covid-19 Market
Due to the COVID-19 pandemic, the global BCG Vaccine for Prevent Covid-19 market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 0.5ml Package accounting for % of the BCG Vaccine for Prevent Covid-19 global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While 0-5 Years Old segment is altered to an % CAGR throughout this forecast period.
China BCG Vaccine for Prevent Covid-19 market size is valued at US$ million in 2021, while the US and Europe BCG Vaccine for Prevent Covid-19 are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe BCG Vaccine for Prevent Covid-19 landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of BCG Vaccine for Prevent Covid-19 include Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, InterVax, Serum Institute of India, GreenSignal, Statens Serum Institute and Shanyao Group and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global BCG Vaccine for Prevent Covid-19 Scope and Segment
BCG Vaccine for Prevent Covid-19 market is segmented by Type and by Application. Players, stakeholders, and other participants in the global BCG Vaccine for Prevent Covid-19 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
Segment by Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
By Company
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
InterVax
Serum Institute of India
GreenSignal
Statens Serum Institute
Shanyao Group
Shanghai Institute of Biological Products
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE